A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
(BE HEARD I)
Recruitment Status: recruiting as of August 2020.
Estimated Completion Date: May 2023
Sponsors and Collaborators: UCB Biopharma SRL
Brief Summary: The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Locations: multiple locations please refer to link above for further information.
Please see link for complete trial details:
Contact: UCB Cares 1844599 ext 2273